Medtronic's 15min Chart Triggers Bollinger Bands Narrowing, KDJ Death Cross

Medtronic's 15-minute chart has exhibited a narrowing of Bollinger Bands, coupled with a KDJ Death Cross at 09/09/2025 14:30. This indicates a reduction in the magnitude of stock price fluctuations and a shift in momentum towards the downside, which may result in further decreases in stock price.

On Monday, September 8, 2025, Medtronic (NYSE: MDT) presented a strategic overview at the Morgan Stanley 23rd Annual Global Healthcare Conference. The company highlighted its financial outlook, strategic priorities, and operational updates. CFO Gary Disbrow expressed optimism about growth prospects while addressing challenges such as margin expansion and strategic investments. Key takeaways from the presentation included Medtronic's plans to spin off its Diabetes business with an IPO expected in early 2026, and significant growth anticipated in Cardiac Ablation Solutions (CAS) and Renal Denervation (RDN).

Medtronic aims for high single-digit EPS growth and improved gross margins, with a focus on return on invested capital (ROIC) and strategic alignment. The company expects to improve gross margins by 3.5 to 4 percentage points over time, returning to pre-COVID levels. The Diabetes Business Spin-off is on track, with systems separation expected by the end of the year. The company is also centralizing supply chain efforts to improve efficiency and predictability. New board committees have been established to focus on growth and operations.

Gary Disbrow emphasized the welcoming culture and high expectations at Medtronic, noting that the transition from a different industry has been smooth. He highlighted the importance of data-driven decision-making and the need to balance growth and margin expansion. The company is positioning itself as a leader in the $11 billion Cardiac Ablation Solutions market and is focusing on developing next-generation technology. For Renal Denervation (RDN), Medtronic is creating centers, training physicians, and conducting consumer awareness campaigns.

The Hugo™ Robotic-Assisted Surgery System is expected to receive U.S. approval by year-end, targeting specific medical fields. The company's collaboration with Elliott Management is set to drive growth through R&D and M&A. The transition to Medtronic has been positive, with Disbrow noting that the company's mission-oriented culture is a strong driving force. He emphasized the importance of understanding the products and customers, and the need to focus on delivering short-term results while identifying long-term growth opportunities.

Medtronic's financial results guidance remains confident, with a commitment to high single-digit EPS growth. The Diabetes Business Spin-off IPO is targeted for the first quarter of 2026, with the spin-off approximately six months later. The Cardiac Ablation Solutions business showed 30% growth in Q4 and 50% in Q1, with expectations for even higher growth in Q2. The company is focusing on incremental M&A, targeting companies with revenue growth and synergies, and leveraging its venture arm for higher-risk investments.

The company's financial results and guidance were presented with a conservative approach, reflecting the impact of tariffs and the separation of the Diabetes business. Medtronic's strategic outlook is focused on growth and operational efficiency, with a strong emphasis on data-driven decision-making and innovation.

References:
Medtronic at Morgan Stanley Conference: Strategic Growth Insights^[1] https://www.investing.com/news/transcripts/medtronic-at-morgan-stanley-conference-strategic-growth-insights-93CH-4230271